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Summary.-The subcutaneous growth of 2 antigenically distinct syngeneic methyl-
cholanthrene-induced murine fibrosarcomas, designated HI and H7, were signific-
antly augmented by the concomitant administration of E. coli endotoxin (LPS).
Amounts as little as 0*02 ,-g i.p. potentiated tumour growth. The weakly antigenic
tumour, Hi, was more susceptible to provocation by LPS than the more strongly
antigenic H7. Maximum provocation of HI tumour growth occurred when LPS was
injected 1 day before the administration of 5000 tumour cells. In contrast, significant
anti-tumour resistance resulted if LPS was administered 6 days before the inocula-
tion of tumour cells. Preliminary evidence indicates that low doses of LPS can
facilitate the "sneaking through" phenomenon. Enhancement of tumour growth could
not be demonstrated with sera or plasma from tumour-bearing mice, unless the
samples were contaminated with endotoxin. The results illustrate the importance of
excluding endotoxin from solutions used in studies of experimental tumours.
THE SUBJECT OF the anti-tumour action
of bacterial endotoxins, the lipopoly-
saccharide (LPS) component of the cell
wall ofGram-negative bacteria, has attrac-
ted much attention ever since Coley
deliberately treated patients with LPS-
containing bacterial culture fluids (Coley,
1891). However, the treatment of cancer
by LPS fell from favour because of incon-
sistent and unpredictable results.
LPS-induced haemorrhagic necrosis of
established experimental tumours is well
documented (Nauts et al., 1953; Shear &
Turner, 1943, Shear, 1943) but differs from
the relatively rare LPS-induced regression
in several ways. For example, regression
induced by LPS is dependent on the
tumour being immunogenic and having
grown to a certain size (Berendt et al.,
1978a, b). A therapeutic effect of LPS
occurs only on subcutaneous and intra-
dermal tumours, but not onintraperitoneal
tumours, and is dependent upon thymus-
derived cells (Parr et al., 1973). A pro-
phylactic effect is achieved only when
LPS is administered i.p. (Parr et al., 1973).
Thus, bacterial endotoxins may inhibit
the development of tumours, depending
upon the type of tumour, dose and route
of injection of LPS, and the interval
between the administration of toxin and
the time tumours have grown to a critical
size.
Nevertheless, despite the attention given
to the anti-tumour effects of endotoxins
during past decades, only scant attention
has been given to the fact that endotoxins
may also potentiate tumour growth, es-
pecially ifadministered at or near the time
of tumour transplantation. Few studies
have been made of the augmentation of
tumour growth and the prolongation of
graft survival by LPS. For example,
Floersheim (1967) found that the adminis-
tration of pertussis vaccine concomitant
with an inoculation of lymphoma cells,
increased the incidence of tumour takes.
Thomson et al. (1978) reported that the
normal rejection of allogeneic skin grafts
in CBA mice could be prevented if LPS
was injected into the mice before and after
skin grafting. The significance and implica-R. KEARNEY AND P. HARROP
tions of this increased susceptibility has
been largely overlooked in studies of
experimental tumours.
Increased susceptibility also occurs for
various other systems, including the provo-
cation of certain latent infections by
typhoid and pertussis vaccines (Dubos &
Schaedler, 1956; Wilson, 1967).
Ourinterestinthe activities ofendotoxin
arose from the observation that serum
from tumour-bearing mice, or from hyper-
immunized mice failed to enhance the
growth of tumours in normal mice unless
the serum contained endotoxin, and was
injected at or near the time ofthe inocula-
tion oftumour cells.
We wish to report that even small
amounts of LPS can profoundly augment
the growth of weakly antigenic tumours.
Therefore, agents (e.g. immune serum,
trypan blue and carrageenan) used in
studies of enhancement or augmentation
of tumour growth may produce effects
which are difficult to interpret if such
agents are contaminated with endotoxin.
The following experiments illustrate the
importance of excluding LPS from solu-
tions or preparations injected into mice
concomitantly with weakly antigenic
tumour cells.
MATERIALS AND METHODS
Mice.-Male inbred CBA/H-WEHI (H-2k)
mice, 2-3 months old, were used in all
experiments.
Tumours.-Two 3-methylcholanthrene-in-
duced tumours designated HI and H7 were
used. Tumour cells were obtained by dis-
aggregating tumour fragments with pronase,
as previously described (Kearney et al., 1975).
Two different doses were examined for each
tumour. Forthe weakly antigenic HI tumour,
a threshold dose of 0.5 x 105 cells developed
tumours in all mice within 2 weeks, whilst
a low dose of 0 05 x 105 cells generally failed
to develop palpable tumours within this
period. The threshold dose for the strongly
antigenic H7 tumour was 106 cells, whilst
105 cells was chosen for low dose. Washed
tumour cells were suspended in 0-2 ml serum-
free Dulbecco's modified Eagles' medium and
injected s.c. along the midline ofthe abdomi-
nal wall. Tumour growth was monitored by
measuring, with a Schnelltaster dial gauge
(Wu & Kearney, 1979) the greatest and the
smallest diameters, and taking the mean.
The values recorded have been corrected for
skin thickness.
Lipopolysaccharide (LPS).-Lipopoly-
saccharide B, E. coli 055B5 (Difco Labora-
tories, Detroit, Mich., U.S.A.) was dissolved
in pyrogen-free saline (Travenol Laboratories,
Sydney, Australia) at the concentrations
indicated for particular experiments. Mice
were injected i.p. with 0 1 ml, 1 h before
tumour inoculation.
Serum and plasma.-While mice were
under ether anaesthesia, blood was collected
aseptically from the heart with sterile dis-
posable needles and plastic syringes, 12-14
days after s.c. injection of 105 HI tumour
cells or 106 H7 tumour cells. Plasma was
obtained from normal (NMP) or tumour-
bearing mice (TBP) by adding preservative-
free heparin (Weddel Pharmaceuticals Ltd,
London) to freshly collected blood (10 u/ml).
All blood collected was transferred to sterile
disposable centrifuge tubes. Tumour-bearer
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FiG. 1. Effect of single i.p. injection of dif-
ferent doses of E. coli endotoxin (LPS) on
the s.c. growth of 5000 Hi tumour cells
in CBA males. LPS administered 1 h
before tumour challenge. Eight mice per
group. 0, untreated controls; 0, 20 ,ug
LPS; E, 2 ,ug LPS; , 0-2 ,ug LPS;
O, 0-02 ,ug LPS; A, 0-002 ,ug LPS.
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serum (TBS) and normal serum (NMS) from
contracted clots, and plasma from whole
blood, were then centrifuged and transferred
to sterile disposable plastic screw-capped
containers and stored at -70°C. On the day
of the experiment, recipient mice were
injected i.p. with 0 5 ml serum or plasma less
than 1 h before tumour inoculation. Endo-
toxin-contaminated serum (or plasma) was
simulated by adding LPS to pyrogen-free
sterile serum, or by injecting LPS into mice
at the same time as the injection of pyrogen-
free serum. The absence of endotoxins from
the serum and plasma samples was estab-
lished by the Limulus amoebocyte lysate
assay (Sigma Chemicals Co., St Louis, Ma)
after the samples were extracted with chloro-
form to remove inhibitors.
RESULTS
Effect of various doses of LPS on the
growth of0.05 x 105 HI tumour cells in mice
Eight mice in each of 5 groups were
injectedi.p. with 20, 2, 0-2, 0-02 or 0-002 ,ug
Number of
HI tumour
cells
Averago
tumour in
LPS-treated
mice
Tumour size
Mean + s.e.
(0.1 mm)
Tumour
incidence
(Day 14)
Average
tumour
in
normal
mice
5000 1000 500
of LPS, shortly before s.c. inoculation
with 0.05 x 105 Hi tumour cells. Results
shown in Fig. 1 demonstrate that as little
as 002 ,ug LPS can significantly augment
the growth of the HI tumour. Increasing
the dose ofLPS to 2 ,ug reduced the latent
period of induction of tumours, and
profoundly augmented the growth. How-
ever, further increase in the amount of
LPS only marginally affected the subse-
quent growth rate and the time at which
tumours became palpable.
Effect of LPS on the growth of different
doses ofHi tumour cells in mice
Mice in each of 6 groups were injected
i.p. with 2 p,g LPS, 1 h before a s.c.
inoculation of 5, 50, 100, 500, 1000 or
5000 (= 0-05 x 105) Hi tumour cblls.
Control mice, untreated with LPS, were
injected similarly with the same number
of tumour cells. At daily intervals after 4
days, mice were examined for palpable
100 50 5
148+16 135+12 130+9 75+6 107+8 49
8/8 8/8 11/12 3/12 5/12 1/12
Tumour size
Mean+s.e.
(01 mm) 85+7 65+5 45+4 0 0 0
Tumour
incidence
(Day 14) 8/8 3/8 5/12 0/12 0/12 0/12
Fia. 2.- Effect of single i.p. injection of 2 ,ug E. coli endotoxin (LPS) on the incidence and s.c. growth
of various doses of Hi tumour cells. The mean diameters are given for tumours measurable 14 days
after tumour-cell inoculation.
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tumours. Tumours were measured daily
until Day 14, when all tumour-bearing
mice were killed. Fig. 2 shows the sig-
nificant potentiating effect on tumour
growth, of LPS, seen as an increase in
both the incidence and size of HI tumours
in LPS-treated mice. About half the un-
treated control mice, injected with 1000 or
500 cells, developed significantly smaller
tumours than those in virtually all the
corresponding LPS-treated mice. Control
mice, injected with fewer than 500 cells,
did not develop tumours by Day 14. In
contrast, about half the LPS-treated mice
developed tumours from as few as 50 cells.
It is noteworthy that the mean size as
well as the incidence ofthe tumours in the
LPS-treated mice, injected with 50 cells,
was greater than that of similar mice
injected with 100 cells.
Effect of LPS, administered at different
intervals relative to HI tumour inoculation,
on the subsequent tumour growth in mice
Eight mice in each of 8 groups received
a single i.p. injection of 2 ,ug LPS on
Days 7, 6, 5, 4, 3, 2, 1 or 4 h before tumour
inoculation. Mice in Group 9 received LPS
at the same time as tumour inoculation
(Day 0) whilst mice in Groups 10, 11 and
12 were injected with LPS, 4 h, 1 day and
2 days, respectively, after the injection of
tumour cells. All mice, including 8 which
received no LPS, were injected s.c. with
5000 HI tumourcellsonDay0. Thegrowth
rates of the tumours were monitored daily
for 15 days. Results shown in Fig. 3
demonstrate both immunostimulating and
immunosuppressive effects of LPS on the
growth of the HI tumour. The effects
depended on the time of administration of
LPS relative to the time of tumour-cell
inoculation. Immunostimulation by LPS
was shown either as failure of the tumours
to grow, or as arelatively long latentperiod
before tumours became palpable. Maxi-
mum immunostimulation was produced
when LPS was administered on Day 6
before the injection of tumour cells, but
was almost absent if LPS was adminis-
tered on Day 7. A slower, progressive
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FiG. 3.-Effect of single i.p. dose of 2 ,ig
E. coli endotoxin (LPS), administered at
different intervals relative to the s.c. inocu-
lation of 5000 HI tumour cells, on subse-
quent tumour growth. Each point rep-
resents the mean value for 8 mice in normal
(0) and LPS-treated mice (*), 15 days
after tumour inoculation.
decrease in immunostimulation occurred
when LPS was administered between Days
5 and 2 before the injection oftumour cells.
On Day 1, before tumour-challenge,
LPS produced maximum immunosup-
pression, as evidencedbothby the develop-
ment of large tumours and a shorter
induction period (results not shown).
Theimmunosuppression steadily decreased
if LPS was administered during the 2-day
period after tumour challenge. Analysis of
the growth rates of all the established
tumours (results not shown) indicated that
they were all similar, i.e. regression of
established tumours in either control mice
or LPS-treated mice did not occur.
Effect ofLPS in TBP or NMP injected into
mice before challenge with 0 5 x 105 HI
tumourcells
Six mice in each of4groupswereinjected
with either NMP or TBP with or without
20 ,ug LPS. Mice in a 5th group were
562
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FIG. 4.-Effect of single i.p. dose of 20 jug
E. coli endlotoxin (LPS) on o.c. growth of
05 5x 105 Hi tumour cells in CBA males
injected i.p. with plasma from either normal
(NMP) or Hi-tumour-bearing mice (TBP).
6 mice per group. *, untreated controls;
*, 0 5 ml NMP alone; *, 0 5 ml TBP
alone; 0, LPS; A, LPS+NMP; O, LPS
+TBP.
injected i.p. with 20 ,ug LPS alone. All
mice, including a group ofuntreated mice,
were injected s.c. with 0.5 x 105 Hi
tumour cells soon after LPS and plasma
administration. Fig. 4 shows that NMP
and TBP alone had no significant effect
on the growth ofthe Hi tumour. However,
the addition of LPS, either alone or
admixed with NMP or TBP (to simulate
contamination) significantly augmented
tumour growth. Similar results were
obtained when TBS or NMS was used
(results not shown).
Effect ofLPS on the growth of0.05 x 105 H 1
tumour cells in mice pretrecated with NMIP
orTBP
Six mice in each of 6 groups were
treated as in the previous experiment,
except that all mice were challenged with
a low dose of 0 05 x 105 Hi tumour cells.
Fig. 5 shows that neither TBP nor NMP
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FIG. 5.-Effect of single i.p. dose of 20 pg E.
coli endotoxin (LPS) on s.c. growth of 0.05
x 105 HI tumour cells in CBA males
injected i.p. with plasma from either normal
(NMP) or HI-tumour-bearing mice (TBP).
6 mice per group. 0, untreated controls;
A, 0 5 ml NMP alone; *, 0 5 ml TBP
alone; 0, LPS; A, LPS+NMP; D, LPS
+TBP.
induced tumour growth, but 20 ,ug LPS
administered either alone, or with NMP or
TBP, caused the low dose of tumour cells
to become established and grow pro-
gressively in all such mice. Similar results
were obtained with NMS and TBS (results
not shown).
Effect of LPS on the growth of 105 H7
tumour cells in mice pretreated with NMP
orTBP
Six mice in each of6 groups were treated
with 20 jug LPS, NMP or TBP as in the
preceding experiment, and then challenged
with 105 cells ofthe strongly antigenic H7
tumour. Fig. 6 shows that 105 H7 tumour
cells developed into small tumours which
grew initially and then regressed. Pre-
treatment with H7 TBP did not sig-
nificantly affect the rate of growth or
regression. However, injection of LPS,
alone or admixed with NMP or TBP, pre-
vented the regression of the H7 tumours.
The same results were obtained with NMS
or TBS (results not shown). In similar
experiments, 20 jig LPS, injected alone or
admixed with NMP or TBP, did not
significantly augment the growth of 106
H7 tumour cells, though TBP without
LPS had a slight inhibitory effect on the
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FIG. 6.-Effect of single i.p. dose of 20 jug
E. coli endotoxin (LPS) on s.c. growth of
105 H7 tumour cells in CBA males injected
i.p. with plasma from either normal (NMP)
or H7-tumour-bearing mice (TBP). 6 mice
per group. 0, untreated controls; A
0 5 ml NMP alone; E, 0 5 ml TBP alone;
0, LPS; A, LPS+NMP; Li, LPS+TBP.
growth ofthe same number oftumour cells
in mice (results not shown).
DISCUSSION
Endotoxin,thelipopolysaccharide (LPS)
component of the cell wall of Gram-
negative bacteria, possesses a number of
biological activities; it is a pyrogen, an
adjuvant, and an inducer of tumour
necrosis and lethality in experimental
animals (Neter, 1969). Bacterial endo-
toxins may facilitate or inhibit the patho-
genicity of infection, depending on the
infecting micro-organism, dose and route
of injection of endotoxin, and the interval
between administration of toxin and
initiation of infection (see reviews by
Rowley, 1964; Nowotny, 1969; Cluff,
1970). Characteristically, this resistance
to infection by parasites, viruses, bacteria
and fungi involves a transient decrease
followed by a more prolonged increase in
resistance to infection. The biphasic
changes in resistance parallel changes in
the clearance of foreign substances from
the blood by the reticuloendothelial (RE)
system (Halpern et at., 1953; Biozzi et al.,
1955). After i.v. injection ofendotoxin and
colloids, RE clearance is depressed for a
few hours; this is followed by an increase
in the phagocytic function of the RE cells
for about 1 week. The initial depression
of the RE system is often referred to as a
"blockade"; its later enhancement is
associated with an increase in number of
phagocytic cells and an acceleration ofthe
phagocytic activity of individual macro-
phages (Rowley, 1962; Austen & Cohn,
1963).
Since macrophages are potentially im-
portant effector cells in the host response
to neoplastic growth (e.g. Hibbs et al.,
1978) any alteration in their numbers or
function would be likely to affect tumour
growth.
Leucocytic migration into areas of
inflammation is also impaired by injection
of LPS (Conti et al., 1961). Therefore, the
transient granulocytopenia induced by
endotoxin may also influence resistance to
tumours.
LPS provocation ofthe growthofweakly
antigenic HI tumours from relatively few
cells begs a heuristic outlook. For example,
vaccination by typhoid and pertussis
vaccines, and diseases caused by Gram-
negative bacteria (e.g. E. coli urinary-tract
infections) may permit foci of weakly
antigenic neoplastic cells to escape early
destruction. Compelling evidence has led
Hibbs et al. (1978) to propose a mechanism
ofnon-specific immunesurveillanceagainst
tumours. Therefore, under certain condi-
tions, a temporary depression of such a
mechanism by LPS may be an important
factor in the carcinogenesis of tumours in
man's environment. It is noteworthy that
exposure to LPS not only augmented the
growth of relatively large numbers of
weakly antigenic HI tumour cells, but
also facilitated the escape ofrelatively few
cells from the anti-tumour mechanisms in
normal mice. The greater incidence of
significantly larger tumours in LPS-
treated mice injected with 50 HI tumour
cells, than in LPS-treated mice injected
with either 100 or 5tumour cells, resembles
the "sneaking through" effect (Klein, 1966;
Naor, 1979). The extent to which LPS
facilitates the "sneaking through" effect
could not be determined, however, since
none of the control mice injected with
fewer than 500 cells developed tumours
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during the relatively short observation
period. Nevertheless, it is conceivable
that LPS may augment the growth of
small foci of tumour cells by facilitating
"sneaking through", before the subsequent
activation ofmacrophages by LPS controls
the ensuing tumour growth.
The modulation of host susceptibility
to tumour growth is consistent with that
reported for LPS on the susceptibility to
bacterial infection (Cluff, 1970) except that
the period during which provocation of
tumour growth occurred was of a longer
duration than that reported for bacterial
infections. Thus, whilst increased sus-
ceptibility to infection persists only for
several hours before and after exposure to
LPS, provocation of HI tumour growth
extended from one day before to at least
2 days after exposure to LPS.
The observed prophylactic effect of
LPS against tumour growth is similar to
that reported by many investigators (e.g.
Old et al., 1961; Weiss et al., 1961; Parr
et al., 1973) and is probably related to
enhanced macrophage and RE activity a
few days after exposure to LPS (Rowley,
1962; Cluff, 1970). The tumoricidal effects
induced in cultured macrophages by LPS
(Weinberg et al., 1978) are not apparent
in vivo until some 6 days after the adminis-
tration of LPS. In fact, the non-specific
anti-tumour immunity found during the
early development of syngeneic tumour
isografts (Nelson & Nelson, 1978; Wu &
Kearney, 1979) seems to be inhibited by
the effects of LPS. Similar inhibition of
resistance occurs when low doses of H1
tumour cells are injected with a mixture
of non-replicating mitomycin C-treated
HI tumour cells, or injected alone into
carrageenan-treated normal mice (Wu &
Kearney, 1979) or trypan blue-treated
(Wu & Kearney, 1980) normal mice. Thus,
it seems that soon after administration
LPS affects the same mechanisms of non-
specific resistance as those methods or
agents which thwart macrophage function
and augment tumourgrowth. Althoughthe
exact mechanism by which LPS augments
tumour growth is not known, the principal
mechanism responsible for the transient
decreases in resistance to bacterialinvasion
following administration of endotoxin
(Dubos & Schaedler, 1956) is believed to be
interference with granulocytic diapedesis
and exudation, as well as inhibition of
phagocytosis by macrophages (Cluff, 1970).
In the present experiments, 0-02 ,tg
LPS significantly augmented the growth
of low numbers of the weakly antigenic
HI tumour cells. The time between tumour
inoculation and the development of palp-
able tumours could be shortened by
increasing the amount of LPS to 2 pg.
Further increasing the amount of LPS
to 20 /tg only marginally altered this
interval and the subsequent growth rate
of tumours. The results illustrate that in
studies involving augmentation of tumour
growth, care should be taken to avoid
contaminating serum or other agents with
LPS (e.g. from glassware) since very
minute amounts can significantly alter the
subsequent growth of weakly antigenic
tumours. Therefore, reports (e.g. Moller,
1964) which claim to demonstrate immu-
nological enhancement of syngeneic
tumours by immune serum without includ-
ing a control of normal serum, or without
a knowledge of the extent serum is con-
taminated with endotoxin, should be
viewed with some caution.
The importance ofendotoxin contamina-
tion in reagents used in biological research
has been demonstrated by several groups
(Bito, 1977; Weinberg et al., 1978;
]Donahoe & Peters 1979). Donahoe and
Peters (1979) found that endotoxin con-
tamination could account for the inhibi-
tion of anti-viral cell-mediated immune
responses, measured either by the lympho-
cyte-transformation assay in vitro, or by
the footpad-swelling assay in vivo. Endo-
toxin administered before tumour chal-
lenge will abrogate specific immunity
acquired either by tumour excision, or by
the injection of mitomycin C-treated
tumour cells (Kearney & Harrop, to be
published).
The phenomenon of allogeneic graft
enhancement (Kaliss, 1962) though demon-
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strated in few syngeneic systems (Moller,
1964; Attia & Weiss, 1966; Bubenik &
Koldovsky, 1965; Bubenik et al., 1965)
has led to the idea that humoral responses
augment tumour growth. The idea has
been further reinforced by the reports that
sera from tumour-bearing animals can
"block", in an immunologically specific
manner, the anti-tumour cytotoxicity of
specifically sensitized lymphocytes in vitro
(Hellstrom & Hellstrom, 1969). Similar
tumour-bearer sera, however, were found
not to inhibit the weak cell-mediated
immunity to the HI tumour in vivo
(Kearney et al., 1979). We propose that
enhancement, often attributed to anti-
bodies to some syngeneic tumours, may
in some cases be due to contamination of
serum byendotoxin, especially ifthe serum
is administered at or just before tumour
grafting. This possibility is further streng-
thened by the observation that the normal
rejection of allogeneic skin grafts in CBA
mice can be prevented if LPS is injected
into mice before and after skin grafting
(Thomson et al., 1978).
It is noteworthy that enhancement has
been used as a sensitive test to demon-
strate weak antibodies to tumour antigens
(Moller, 1964) and also to detect cross-
reacting antigens after the administration
of tumour-cell extracts (Attia & Weiss,
1966). It is conceivable, therefore, that
without adequate controls, biological
products, including sera, contaminated
with endotoxin may account for similar
enhancement ofweakly antigenic tumours.
Such tumours may also be susceptible to
antibody-mediated enhancement, but not
necessarily share common tumour-specific
antigens.
Since endotoxins, even in minute
amounts, have a variety of effects (Cluff,
1970) the use ofpreparations contaminated
with such ubiquitous substances can lead
to erroneous conclusions in tumour re-
search. Thus, preparations including sera
or their fractions which enhance tumour
growth should be tested to exclude endo-
toxin before the enhancing phenomenon
can be regarded as being due to antibody
or some other serum factor. Furthermore,
positive anti-tumour effects by immune
sera may be negated by the presence of
endotoxin contamination, especially when
tumours are weakly antigenic. Therefore,
the use of endotoxin-contaminated pre-
parations should be avoided in tumour
research, unless it is shown that the par-
ticular system is insensitive to such sub-
stances.
This work was supported by grants from the
University of Sydney Cancer Research Committee,
and the Medical Research Committee of the Univer-
sity of Sydney.
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